XORTX Therapeutics Inc. SEC filings XRTX
XORTX Therapeutics Inc. has 291 filings in SEC EDGAR's recent list, going back to Jan 25, 2018. Its latest annual report, Form 20-F, was filed on Mar 20, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 8, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 13, 2026 | — |
| EFFECT | Filing | Feb 17, 2026 | — |
| CORRESP | Letter to the SEC | Feb 12, 2026 | — |
| UPLOAD | Letter from the SEC | Aug 5, 2025 | — |
| DRS | Filing | Jul 30, 2025 | — |
| NT 20-F | Filing | May 1, 2025 | Dec 31, 2024 |
| EFFECT | Filing | Nov 25, 2024 | — |
| CORRESP | Letter to the SEC | Nov 22, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 20, 2024 | — |
| D | Filing | Oct 31, 2024 | — |
| NT 20-F | Filing | May 1, 2024 | Dec 31, 2023 |
| EFFECT | Filing | Aug 7, 2023 | — |
| EFFECT | Filing | Aug 7, 2023 | — |
| EFFECT | Filing | Feb 3, 2023 | — |
| CORRESP | Letter to the SEC | Feb 1, 2023 | — |
| UPLOAD | Letter from the SEC | Jan 31, 2023 | — |
| EFFECT | Filing | Sep 30, 2022 | — |
| EFFECT | Filing | Sep 22, 2022 | — |
| CORRESP | Letter to the SEC | Sep 22, 2022 | — |
| CORRESP | Letter to the SEC | Sep 22, 2022 | — |
| CORRESP | Letter to the SEC | Sep 21, 2022 | — |
| CORRESP | Letter to the SEC | Sep 19, 2022 | — |
| CORRESP | Letter to the SEC | Sep 19, 2022 | — |
| CORRESP | Letter to the SEC | Sep 14, 2022 | — |
| CORRESP | Letter to the SEC | Sep 8, 2022 | — |
| CORRESP | Letter to the SEC | Sep 8, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 16, 2022 | — |
| DRS | Filing | Aug 15, 2022 | — |
| NT 20-F | Filing | May 3, 2022 | Dec 31, 2021 |
| SEC STAFF LETTER | Filing | Oct 12, 2021 | — |
| EFFECT | Filing | Oct 12, 2021 | — |
| CERT | 8a cert | Oct 12, 2021 | — |
| CORRESP | Letter to the SEC | Oct 8, 2021 | — |
| CORRESP | Letter to the SEC | Oct 8, 2021 | — |
| 8-A12B/A | Filing | Oct 4, 2021 | — |
| 8-A12B | Filing | Sep 29, 2021 | — |
| CORRESP | Letter to the SEC | Sep 16, 2021 | — |
| UPLOAD | Letter from the SEC | Sep 1, 2021 | — |
| SEC STAFF LETTER | Filing | Aug 13, 2021 | — |
| CORRESP | Letter to the SEC | Aug 11, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 2, 2021 | — |
| DRS/A | Filing | Jul 21, 2021 | — |
| DRSLTR | Filing | Jul 20, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 28, 2021 | — |
| DRS | Filing | May 26, 2021 | — |
| D | Filing | Jan 25, 2018 | — |
Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- XRTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Vancouver, British Columbia, Canada
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1729214
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.